Elicio Therapeutics (ELTX) presented updated results from its phase 1 AMPLIFY-201 clinical trial of ELI-002 in individuals with mutant KRAS-driven colorectal or pancreatic cancer.
ELI-002 is designed as an off-the-shelf vaccine to target KRAS mutations, a driver in approximately 25% of all solid tumors.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.